Shots:

• The approval is based on the ICONIC study as well as 5yrs. of data from supportive studies that evaluate Livmarli in 86 patients with ALGS
• The results from the ICONIC study demonstrated a significant reduction in pruritus that was maintained through 4yrs.
• Livmarli is the first FDA-approved therapy for patients aged ≥1yrs. & the company has received a rare pediatric disease priority review voucher. The therapy will now be accessible to patients with a prescription through MAP that provides insurance coverage- and access support along with financial support options for patients with Livmarl

­ | Ref: Mirum  | Image: Businesswire